Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Large Increase in Short Interest

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 79,000 shares, an increase of 101.5% from the March 31st total of 39,200 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average daily volume of 206,900 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday. They issued a “sell” rating for the company.

Galmed Pharmaceuticals Price Performance

Shares of Galmed Pharmaceuticals stock remained flat at $0.39 on Friday. 27,223 shares of the stock traded hands, compared to its average volume of 260,258. The firm has a 50-day moving average of $0.36 and a 200-day moving average of $0.38. Galmed Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $7.80.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.